Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprutumab ixadotin in advanced solid tumors
NCT02368951Phase 1Terminated
- Sponsor
- Bayer
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of aprutumab ixadotin in solid tumor (advanced stage) and triple-negative breast cancer (TNBC), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose up to 2 years, Number of subjects with adverse events up to 2 years and 1 more. Started Mar 2015; status: terminated.
02
Drugs
aprutumab ixadotin
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02368951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368951.